home About Us People Portfolio News Contact Us Fund I Investor Login » Fund II Investor Login » Fund III Investor Login »

news

Nov10TriVascular Technologies, Inc. and CRG LP Amend and Restate Term Loan Facility


Santa Rosa, CA, November 10, 2014 – TriVascular Technologies, Inc. (Nasdaq: TRIV) and CRG LP (formerly known as Capital Royalty) and its affiliate funds (“CRG”) today announced that they have amended and restated the term loan facility under which TriVascular previously borrowed $40 million in October 2012.  In connection with this amendment, the company will increase its borrowings under the facility by $10 million upon closing of the transaction, which is anticipated to be completed by the end of the month, subject to customary closing conditions.  Additionally, subject to the achievement of certain revenue milestones, TriVascular will have an option to access up to an additional $15 million on or before December 31, 2015.  This amendment extends the maturity date under the facility from September 30, 2017 to June 30, 2020, reduces the interest rate from 14.0 percent to 12.5 percent, and extends the interest only payment period through September 30, 2018. In addition, certain financial and other covenants were modified.

“Together with the proceeds of our initial public offering, this financing further enables us to continue our focus on commercialization of the Ovation Prime® Stent Graft System and aggressively pursue our product and clinical development initiatives,” said Christopher G. Chavez, TriVascular’s President and Chief Executive Officer.  “We appreciate CRG’s ability to provide flexible financing solutions to support our efforts to make EVAR better, safer and available to more patients with abdominal aortic aneurysms. They have been a valued strategic partner, and we look forward to working with them for years to come.”

“CRG is excited to expand our longstanding partnership with TriVascular as they continue their commercialization and development of the Ovation® technology platform,” said Charles Tate, Chairman and Founder of CRG.  “Our investment in TriVascular furthers our mission of working with world-class management teams to drive greater innovation in healthcare.”

About TriVascular Technologies, Inc. - TriVascular is a medical device company developing and commercializing innovative technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms. The company manufactures the Ovation Prime Abdominal Stent Graft System, the lowest profile FDA-approved endovascular aortic repair (EVAR) system, which utilizes a novel, polymer-based sealing mechanism. TriVascular is based in Santa Rosa, California.

About CRG - Founded in 2003, CRG (previously known as Capital Royalty L.P.) is a healthcare-focused investment firm with $1.5 billion of assets under management that provides capital to healthcare companies primarily through structured debt and senior secured loans. CRG works across the spectrum of life science products and technologies and targets investment sizes ranging between $20 million and $200 million. The firm partners with commercial-stage healthcare companies to provide flexible financing solutions so they can achieve their growth objectives. CRG is headquartered in Houston, Texas with offices in Boulder, Colorado and New York City. For additional information, please visit www.crglp.com.

 

Company Contact:


Michael R. Kramer
Chief Financial Officer
(707) 543-8709

Media Contact: 

 

Vivek K. Jayaraman
VP, Global Sales & Marketing
(707) 543-8804
vivek.jayaraman@trivascular.com

Investor Relations Contact:


Westwicke Partners
Jamar Ismail
(415) 513-1280
Jamar.ismail@westwicke.com

CRG Contact:


Luke Duster
Managing Director
(713) 209-7361
lduster@crglp.com


Disclaimer


This message does not constitute an offer to sell or buy any securities and may not be used or relied upon in connection with any offer or sale of securities. It does not constitute a solicitation of clients and may not be used or relied upon in connection with any solicitation of clients. This message does not purport to be complete.